Wright GFR Estimation Tool

Clinical calculation support · Verify results before clinical use

Patient parameters

Enter the patient measurements and serum creatinine. Confirm the laboratory assay method before interpreting the result.

Published Wright equation reference range: 20–80 years.
Equation coding: male = 0; female = 1.
Use a current laboratory result and verify the assay method.
mg/dL is converted to µmol/L using × 88.4.

About the Wright equation

The Wright equation was developed to estimate glomerular filtration rate in patients with cancer. This implementation uses the Jaffé creatinine variant without a creatine kinase term and estimates absolute GFR in mL/min.

Equation used

GFR (mL/min) = [(6580 − 38.8 × age) × BSA × (1 − 0.168 × sex)] ÷ SCr

Sex coding: male = 0 and female = 1. Serum creatinine must be expressed in µmol/L. Body surface area (BSA) is calculated with the Du Bois equation:

BSA (m²) = 0.007184 × height(cm)0.725 × weight(kg)0.425

Important interpretation points

  • This is an absolute GFR estimate, not a value indexed to 1.73 m².
  • Wright equation variants differ by creatinine assay and whether creatine kinase is included. The equation must match the laboratory method.
  • This tool does not assign chronic kidney disease stages or provide a medication dose recommendation.
  • Creatinine-based estimates can be unreliable in situations such as unusual muscle mass, rapidly changing kidney function, or when a highly accurate GFR is required.

Unit conversion

Serum creatinine in mg/dL is converted to µmol/L by multiplying by 88.4.

References

Wright JG, Boddy AV, Highley M, et al. Estimation of glomerular filtration rate in cancer patients. British Journal of Cancer. 2001;84:452–459. Full text at PubMed Central
Evaluation of the Cockcroft–Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Annals of Oncology. 2003. Describes Wright variants and comparison with measured GFR. Article page
American Society of Onco-Nephrology. Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology. Clinical Journal of the American Society of Nephrology. 2024;19(8):1061–1072. doi:10.2215/CJN.0000000000000508. DOI / publication page